Silverfin false false 31/01/2025 01/02/2024 31/01/2025 Dr Mohamad Ghanem Aldik 14/01/2020 Farah Ghali 14/01/2020 23 June 2025 The principal activity of the Company during the financial period was the provision of medical services. 12403926 2025-01-31 12403926 bus:Director1 2025-01-31 12403926 bus:Director2 2025-01-31 12403926 2024-01-31 12403926 core:CurrentFinancialInstruments 2025-01-31 12403926 core:CurrentFinancialInstruments 2024-01-31 12403926 core:ShareCapital 2025-01-31 12403926 core:ShareCapital 2024-01-31 12403926 core:RetainedEarningsAccumulatedLosses 2025-01-31 12403926 core:RetainedEarningsAccumulatedLosses 2024-01-31 12403926 core:OfficeEquipment 2024-01-31 12403926 core:ComputerEquipment 2024-01-31 12403926 core:OfficeEquipment 2025-01-31 12403926 core:ComputerEquipment 2025-01-31 12403926 2023-01-31 12403926 bus:OrdinaryShareClass1 2025-01-31 12403926 2024-02-01 2025-01-31 12403926 bus:FilletedAccounts 2024-02-01 2025-01-31 12403926 bus:SmallEntities 2024-02-01 2025-01-31 12403926 bus:AuditExemptWithAccountantsReport 2024-02-01 2025-01-31 12403926 bus:PrivateLimitedCompanyLtd 2024-02-01 2025-01-31 12403926 bus:Director1 2024-02-01 2025-01-31 12403926 bus:Director2 2024-02-01 2025-01-31 12403926 core:OfficeEquipment core:TopRangeValue 2024-02-01 2025-01-31 12403926 core:ComputerEquipment core:TopRangeValue 2024-02-01 2025-01-31 12403926 2023-02-01 2024-01-31 12403926 core:OfficeEquipment 2024-02-01 2025-01-31 12403926 core:ComputerEquipment 2024-02-01 2025-01-31 12403926 bus:OrdinaryShareClass1 2024-02-01 2025-01-31 12403926 bus:OrdinaryShareClass1 2023-02-01 2024-01-31 iso4217:GBP xbrli:pure xbrli:shares

Company No: 12403926 (England and Wales)

LUNG HEALTH SURREY LIMITED

Unaudited Financial Statements
For the financial year ended 31 January 2025
Pages for filing with the registrar

LUNG HEALTH SURREY LIMITED

Unaudited Financial Statements

For the financial year ended 31 January 2025

Contents

LUNG HEALTH SURREY LIMITED

STATEMENT OF FINANCIAL POSITION

As at 31 January 2025
LUNG HEALTH SURREY LIMITED

STATEMENT OF FINANCIAL POSITION (continued)

As at 31 January 2025
Note 2025 2024
£ £
Fixed assets
Tangible assets 3 8,248 6,034
8,248 6,034
Current assets
Debtors 4 8,728 6,554
Cash at bank and in hand 157,746 111,541
166,474 118,095
Creditors: amounts falling due within one year 5 ( 25,512) ( 22,494)
Net current assets 140,962 95,601
Total assets less current liabilities 149,210 101,635
Provision for liabilities 6 ( 2,062) ( 1,509)
Net assets 147,148 100,126
Capital and reserves
Called-up share capital 7 100 100
Profit and loss account 147,048 100,026
Total shareholders' funds 147,148 100,126

For the financial year ending 31 January 2025 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The financial statements of Lung Health Surrey Limited (registered number: 12403926) were approved and authorised for issue by the Board of Directors on 23 June 2025. They were signed on its behalf by:

Dr Mohamad Ghanem Aldik
Director
LUNG HEALTH SURREY LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 January 2025
LUNG HEALTH SURREY LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 January 2025
1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial year, unless otherwise stated.

General information and basis of accounting

Lung Health Surrey Limited (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the Company's registered office is 8 Bullock Crescent, Woking, GU22 9FW, United Kingdom.

The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.

The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.

Going concern

The directors have assessed the Statement of Financial Position and likely future cash flows at the date of approving these financial statements. The directors have a reasonable expectation that the Company has adequate resources to continue in operational existence and to meet its financial obligations as they fall due for at least 12 months from the date of signing these financial statements. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.

Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

Turnover is recognised when the significant risks and rewards are considered to have been transferred to the customer.

Taxation

Current tax
Current tax is provided at amounts expected to be paid (or recoverable) using the tax rates and laws that have been enacted or substantively enacted at the Statement of Financial Position date.

Deferred tax
Deferred tax arises as a result of including items of income and expenditure in taxation computations in periods different from those in which they are included in the Company's financial statements. Deferred tax is provided in full on timing differences which result in an obligation to pay more or less tax at a future date, at the average tax rates that are expected to apply when the timing differences reverse, based on current tax rates and laws. Deferred tax assets and liabilities are not discounted.

The carrying amount of deferred tax assets are reviewed at each reporting date and a valuation allowance is set up against deferred tax assets so that the net carrying amount equals the highest amount that is more likely than not to be recovered based on current or future taxable profit.

Tangible fixed assets

Tangible fixed assets are stated at cost (or deemed cost) or valuation less accumulated depreciation and accumulated impairment losses. Cost includes costs directly attributable to making the asset capable of operating as intended. Depreciation is provided on all tangible fixed assets, other than investment properties and freehold land, at rates calculated to write off the cost or valuation, less estimated residual value, of each asset on a straight-line basis over its expected useful life, as follows:

Office equipment 5 years straight line
Computer equipment 5 years straight line

Residual value represents the estimated amount which would currently be obtained from disposal of an asset, after deducting estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life.

Provisions

Provisions are recognised when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that the Company will be required to settle that obligation and a reliable estimate can be made of the amount of the obligation.

The amount recognised as a provision is the best estimate of the consideration required to settle the present obligation at the Statement of Financial Position date, taking into account the risks and uncertainties surrounding the obligation. Where a provision is measured using the cash flows estimated to settle the present obligation, its carrying amount is the present value of those cash flows (when the effect of the time value of money is material).

When some or all of the economic benefits required to settle a provision are expected to be recovered from a third party, a receivable is recognised as an asset if it is virtually certain that reimbursement will be received and the amount of the receivable can be measured reliably.

2. Employees

2025 2024
Number Number
Monthly average number of persons employed by the Company during the year, including directors 2 2

3. Tangible assets

Office equipment Computer equipment Total
£ £ £
Cost
At 01 February 2024 2,728 5,690 8,418
Additions 0 4,207 4,207
At 31 January 2025 2,728 9,897 12,625
Accumulated depreciation
At 01 February 2024 935 1,449 2,384
Charge for the financial year 545 1,448 1,993
At 31 January 2025 1,480 2,897 4,377
Net book value
At 31 January 2025 1,248 7,000 8,248
At 31 January 2024 1,793 4,241 6,034

4. Debtors

2025 2024
£ £
Trade debtors 8,728 6,554

5. Creditors: amounts falling due within one year

2025 2024
£ £
Amounts owed to directors 3,771 2,327
Accruals 3,277 2,798
Taxation and social security 18,464 17,369
25,512 22,494

6. Deferred tax

2025 2024
£ £
At the beginning of financial year ( 1,509) ( 442)
Charged to the Statement of Income and Retained Earnings ( 553) ( 1,067)
At the end of financial year ( 2,062) ( 1,509)

7. Called-up share capital

2025 2024
£ £
Allotted, called-up and fully-paid
100 Ordinary shares of £ 1.00 each 100 100

8. Related party transactions

Transactions with the entity's directors

2025 2024
£ £
Amounts owed to directors 3,771 2,327